NanoViricides Inc. (NNVC)
| Bid | 1.2 |
| Market Cap | 19.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.73M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -1.78 |
| Forward PE | -1.26 |
| Analyst | Buy |
| Ask | 1.24 |
| Volume | 502,247 |
| Avg. Volume (20D) | 171,627 |
| Open | 1.20 |
| Previous Close | 1.40 |
| Day's Range | 1.16 - 1.26 |
| 52-Week Range | 0.94 - 2.55 |
| Beta | 0.92 |
About NNVC
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for NNVC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
1 week ago · proactiveinvestors.com
NanoViricides touts antiviral NV-387 as tool against new COVID variantNanoViricides (NYSE-A:NNVC) said its experimental antiviral drug NV-387 could play a role in combating emerging threats from COVID-19 and bird flu, as new virus variants raise global health concerns. ...
3 weeks ago · proactiveinvestors.com
NanoViricides commissions animal study of broad-spectrum antiviral for measlesNanoViricides (NYSE-A:NNVC) said it is advancing its measles drug development program with a new animal trial to evaluate its antiviral candidate NV-387. The company has commissioned a study using spe...
3 weeks ago · accessnewswire.com
NanoViricides Measles Drug Development Animal Study is ImminentSHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broa...
1 month ago · proactiveinvestors.com
NanoViricides president backs FDA's targeted COVID booster policy shiftNanoViricides (NYSE-A:NNVC) president Dr Anil Diwan has welcomed a new US Food and Drug Administration policy that limits broad COVID-19 vaccine booster recommendations, calling it a “rational and sci...
1 month ago · accessnewswire.com
The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. DiwanSHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.
1 month ago · proactiveinvestors.com
NanoViricides advances NV-387 antiviral program, eyes Phase II trials for MpoxNanoViricides (NYSE-A:NNVC) is preparing a Phase II clinical trial application for its lead antiviral candidate NV-387 to treat Mpox infections in Central Africa, marking a major step in the company's...
1 month ago · proactiveinvestors.com
NanoViricides progresses antiviral portfolio as measles and MPox threats riseNanoViricides Inc (NYSE American: NNVC) said on Wednesday it is moving forward with trials of its antiviral drug NV-387 to combat a growing number of viral threats, including measles and MPox, amid ri...
1 month ago · proactiveinvestors.com
NanoViricides wins ethics approval for Phase II Mpox drug trial in DRCNanoViricides (NYSE-A:NNVC) said on Thursday it has received ethics committee approval in the Democratic Republic of Congo to move forward with a planned Phase II clinical trial of its antiviral drug ...